FDA has approved asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma

Share This Post

August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adults and children aged one month and up who have developed hypersensitivity to E. coli-derived as

The efficacy of JZP458-201 (NCT04145531), an open-label, multi-cohort, multicenter trial in 102 patients with ALL or LBL who had hypersensitivity to E. coli-derived asparaginase as part of a multi-agent chemotherapy regimen, was examined. The average age was ten years, with a range of one to twenty-four years. Rylaze was administered intramuscularly in varied dosages to the patients.

You may like to read : Cancer treatment in India

The achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL was the primary effectiveness outcome measure. Modeling and simulations revealed that with a dosage of 25 mg/m2 injected intramuscularly every 48 hours, 93.6 percent of patients maintained an NSAA of less than 0.1 U/mL 48 hours following a dose of Rylaze (95 percent CI: 92.6 percent , 94.6 percent ).

Abnormal liver tests, nausea, musculoskeletal pain, exhaustion, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia were the most prevalent side effects (incidence > 20%).

The suggested dosage of Rylaze when replacing a long-acting asparaginase product is 25 mg/m2 taken intramuscularly every 48 hours for the needed length of asparaginase activity.

 

Reference: https://www.fda.gov/

Check details here.

 

Take second opinion on leukemia treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy